Scientists create 'Living Biobank' from breast tumors to unlock secrets of drug resistance

NCT ID NCT04133077

Recruiting now Knowledge-focused Sponsor: Centre Jean Perrin Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study takes tumor samples from women with aggressive breast cancers (triple-negative or luminal B) and grows them in mice to create patient-derived xenografts (PDX). The goal is to see how well these mouse models mimic the original tumors and to learn about tumor evolution and resistance. About 85 participants will provide blood and tissue samples, but no new treatment is being tested.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help researchers better understand how breast cancers evolve and resist treatment, potentially guiding future therapies.
What could go wrong: This is an early, observational study with no direct benefit to participants. The mouse models may not fully represent human tumors, limiting what can be learned.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

female breast carcinoma luminal B breast carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER FEMALE

Contacts and locations

Locations

Centre Jean PERRIN
RECRUITING

Clermont-Ferrand, Puy-de-Dôme, 63011, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.